Abstract
A bidirectional detrimental relationship between sleep alteration and Alzheimer’s disease (AD) has been reported in cognitively normal older adults. Here, we tested whether a similar association could be detected in young adults, decades before typical AD symptom onset. We investigated associations between sleep endophenotypes and genome-wide Polygenic Risk Scores (PRS) for AD in 363 young men (22.1±2.7y) devoid of sleep and cognitive disorders. AD PRS was associated with higher slow wave energy, a marker of sleep need, during habitual sleep and following sleep loss, and, potentially, with the relative increase in slow wave energy following sleep deprivation, reflecting sleep homeostasis. Furthermore high AD PRS was correlated with higher daytime sleepiness. These results imply that sleep features may be associated with AD liability in young adults and suggest that, contrary to older adults, denser and/or more intense sleep slow waves are associated with AD risk in early adulthood.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
P.G., M.V., C.S., F.C., C.P. and G.V. are supported by the Fonds de la Recherche Scientifique - FNRS-Belgium. The study was supported by the Wallonia-Brussels Federation (Actions de Recherche Concertées - ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 & T.0242.19 & 3.4516.11), University of Liège (ULiège), Fondation Simone et Pierre Clerdent, European Regional Development Fund (Radiomed project), Fonds Léon Fredericq. DJD is supported by the UK Dementia Research Institute (DRI).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that the data supporting the findings of this study are available from the corresponding author upon request.